[Natural killer activity in B cell type chronic lymphocytic leukemia] NLM AIDSLINE Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[Natural killer activity in B cell type chronic lymphocytic leukemia]

Diss Abstr Int [C]; 54(1):164 1993. Unique Identifier : AIDSLINE ICDB/94690739
Villamor i Casas N; Univ. of Barcelona, Spain


Abstract: Natural killer (NK) cells play a role in immune surveillance against tumoral and infected cells, and display immunoregulatory functions over B and T lymphocytes. In B cell chronic lymphocytic leukemia (B-CLL) there exist immune alterations affecting B and T lymphocytes. Recently NK disfunction was also noticed regarding activity (NKa) and surface phenotype. NKa was analyzed in 67 pts with B-CLL using the 51Cr-release assay and the lymphocytic phenotype by means of CD2, CD4, CD8, CD16, CD11b, CD57, CD56 and CD19. NKa was correlated with clinical and analytical characteristics of pts. The mean age was 68 yr, 36 were males and 31 females. Staging according IWCLL was A 71.6%, B 13.4% and C 10.4%, and 28% of pts fulfilled criteria of latent B-CLL. 36 pts were untreated and 31 were treated (chlorambucil alone or plus prednisone). NKa in B-CLL pts was significantly lower than in controls (19.4% +/- 16.2 vs 40.2% +/- 17.4). A linear inverse relationship was observed between lymphocyte count and NKa. No relation was observed between NKa and other biological parameters. The percentage of NK or T lymphocytes showed a linear relationship with NKa. 13 pts displayed a normal NKa (stage A(0) in 70%). In sequential studies the relationship between NKa and lymphocyte count was also noticed. The group of pts treated displayed similar NKa than untreated ones. Taking it together the low NKa observed in the majority of B-CLL pts may be attributed to dilution of effector lymphocytes by leukemic cells. Recycling capacity of NK cells were studied by prolonging NK assay from 4 to 20 hr. The NKa behavior in B-CLL pts (increase in cytotoxicity) is similar to that observed in controls in contrast that observed in HIV hemophilic pts. Finally, chlorambucil followed by interferon was administered on a group of untreated stage A pts. NKa during interferon treatment became normal without modifications in absolute number T and NK lymphocytes.
Keywords: Aged Antigens, CD Female Human Killer Cells, Natural/*IMMUNOLOGY Leukemia, B-Cell, Chronic/*IMMUNOLOGY Male Phenotype T-Lymphocytes/IMMUNOLOGY THESIS

KWDagedantigens,cdfemalehumankillercells,natural/KWDimmunologyleukemia,b-cell,chronic/KWDimmunologymalephenotypet-lymphocytes/immunologythesis
941130
M94B0788


Copyright © 1994 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .